Bayer AG has patented new potassium channel Kir3.4 (GIRK4; KCNJ5) and/or Kir3.1/3.4 (GIRK1/4; KCNJ3/5) blockers potentially useful for the treatment of heart failure, arrhythmia, primary hyperaldosteronism and hypertension.